Chin Hyok Lee - 11 Aug 2026 Form 4 Insider Report for Lycia Therapeutics, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
26 Oct 2026, 19:00:05 UTC
Prior SEC filing
06 Dec 2024
Next SEC filing
22 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Amy Bachrodt, Attorney-in-Fact
Filing notes and source

Key filing fact

Chin Hyok Lee filed Form 4 for Lycia Therapeutics, Inc. on 26 Oct 2026.

Key facts

  • This page summarizes Chin Hyok Lee's Form 4 filing for Lycia Therapeutics, Inc..
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 26 Oct 2026, 19:00.

Change

  • Previous filing in this sequence was filed on 06 Dec 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002010805 Primary reporting owner

Lee Chin Hyok

Relationship
Chief Medical Officer, 10%+ Owner
Address
C/O LYCIA THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 200, SOUTH SAN FRANCISCO
Signature
/s/ Amy Bachrodt, Attorney-in-Fact
Signature date
26 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+73,191
Change %
Price
$0.000000*
Shares after
73,191
Date
11 Aug 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
73,191
Exercise price
$3.70
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

Footnote F2

The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .